Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

TIR-C: First-in-class targeted therapy for atopic dermatitis

Reference number
Coordinator TIRMED Pharma AB
Funding from Vinnova SEK 0
Project duration August 2025 - September 2025
Status Completed
Venture Global cooperation 2025
Call Planning grant for international proposal 2025

Last updated 3 September 2025

Reference number 2025-01583